Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05801-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Daniele Cattaneo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20…. Hauptthemen laut MEDLINE: Nitriles, Pyrazoles, Pyrimidines, Primary Myelofibrosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
We evaluated RDW in a single-center series of 61 consecutive patients with primary and secondary MF at diagnosis and during treatment with ruxolitinib (RUX) and examined any possible prognostic impact. Elevated RDW values were present in all but 4 patients at diagnosis with a median RDW of 18.9%. RDW was higher in subjects with palpable splenomegaly (p = 0.02), higher ferritin, as well as among those cases who did not receive any cytoreduction before RUX (p = 0.04). Interestingly, higher RDW at diagnosis also correlated with a shorter time from MF diagnosis to RUX start (-4.1 months per one RDW unit; p = 0.03). We observed a modest increase (< 1%) in RDW during the first 6 months of RUX treatment. In a multivariable random-intercept model that considered all time points and contained the covariates time and RUX dose, we also observed a clear decrease in RDW with increasing hemoglobin (Hb) during RUX (slope: -0.4% per g/dL of Hb; p < 0.001). The median RDW at diagnosis of 18.9% was used as a cut-off to identify two subgroups of patients [Group 1: RDW 19.0-25.7%; Group 2: RDW 13.1-18.7%], showing a difference in mortality [Group 1 vs. 2: crude HR 2.88; p = 0.01]. Using continuous RDW at diagnosis, the crude HR was 1.21 per RDW unit (p = 0.002). In a Cox model adjusted for gender, age and Hb at diagnosis, the HR was 1.13 per RDW unit (p = 0.07). RDW may have prognostic significance at MF diagnosis and during RUX, helping in the rapid detection of patients with poor prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Epidemiology Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Myeloproliferative Syndromes Unit, Via Francesco Sforza 35, Milan, 20122, Italy. alessandra.iurlo@policlinico.mi.it.
Zitieren
APA
Cattaneo, D., Galli, N., Bucelli, C., Fidanza, C. A., Bellani, V., Artuso, S., Bianchi, P., Consonni, D., Passamonti, F., & Iurlo, A. (2024). Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib. Annals of Hematology. https://doi.org/10.1007/s00277-024-05801-0
Vancouver
Cattaneo D, Galli N, Bucelli C, Fidanza CA, Bellani V, Artuso S, et al. Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib. Annals of Hematology. 2024. doi:10.1007/s00277-024-05801-0
BibTeX
@article{Cattaneo2024,
author = {Cattaneo, Daniele and Galli, Nicole and Bucelli, Cristina and Fidanza, Cecilia Anna and Bellani, Valentina and Artuso, Silvia and Bianchi, Paola and Consonni, Dario and Passamonti, Francesco and Iurlo, Alessandra},
title = {Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05801-0}
}
EUVIMED